

Idun Pharmaceuticals, Inc.  
Statement of Condition  
as of March 28, 2016

Assets:

|                       |              |
|-----------------------|--------------|
| Cash in Bank          | \$ 62,074.00 |
| Patents **            | Unknown      |
| ABT 199 claim         | Unknown      |
| ABT 263 Royalty       | Unknown      |
| BD Scientific Royalty | Unknown      |
| Total Assets:         | Unknown      |

Liabilities:

|                           |                              |
|---------------------------|------------------------------|
| Unsecured Creditor Claims |                              |
| Bridge Notes              | \$3,724,374.77               |
| License fees              | \$ 115,000.00                |
| Arbitration Award         | \$2,000,000.00               |
| Total Liabilities         | <u><u>\$5,839,374.77</u></u> |
| Equity                    | Unknown                      |

\*\* The patent portfolio excludes the ABT 199 patent, which is the basis for the potential claim for breach of a Research License Agreement